Authors: Erick H Turner
DOI: 10.1371/journal.pmed.0010060
Abstract Summary
A former FDA clinical reviewer of psychotropic drugs argues that the necessary framework for improved drug evaluation already exists within the agency, suggesting internal resources could be better utilized to enhance the review process for psychiatric medications.
Why Brain? ðŸ§
Former FDA reviewer reveals existing taxpayer-funded clinical trials database, potentially improving transparency in psychotropic drug research and public access to trial results.
The image is AI-generated for illustrative purposes only. Courtesy of Midjourney.
